A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia
Clinical trial NCT05091424 · RECRUITING
Trial details
- NCT number
- NCT05091424
- Sponsor
- Hoffmann-La Roche
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2022-03-07
- Primary completion
- 2031-02-10
- Enrollment
- 332
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.